Medicon Hellas S.A. operates in the diagnostics industry that offers instruments, tests, and procedures to clinical and research labs in Greece and internationally. It manufactures, imports, and provides diagnostic and point-of-care test systems, molecular diagnostics, laboratory automation, workflow improvement, and software solutions and services to state and private hospitals and laboratories. The company also produces and exports clinical chemistry, hematology, and immunochemistry reagents. In addition, it offers analyzers, reagents, controls, calibrators, and consumables to biochemistry hematology, immunology, molecular, microbiology, and blood gases sectors; laboratory equipment, such as centrifugal, vortex/shakers, adjustable volume pipettes, and air purifiers; and cosmetics. Further, the company provides service/refurbishment, diagnostic labs, and informatics/software services. Medicon Hellas S.A. was incorporated in 1988 and is headquartered in Gerakas, Greece.…
What Is Novartis (SWX:NOVN) Gaining From Its PMR Approval And ADC Deal?
Medicon Hellas (ATH: MEDIC) is listed on Athens Exchange, where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 152 employees.
The shares were at 3.090 EUR on 20 November 2026, up 19.3% over 52 weeks. Its 52-week range is 2.320 EUR to 3.220 EUR: the price is 4.0% below the high and 33.2% above the low.
At a market capitalisation of 13.66M EUR, it trades at 18.1 times trailing earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.5, a discount of 26% for MEDIC. It pays a dividend yielding 4.81%, against a median of 1.95% among the dividend payers in that peer group.
Medicon Hellas reports return on equity of 12.4%, an operating margin of 16.3% and revenue up 7.6% year over year.
It holds more cash than debt, a net cash position of 2.85M EUR.
No upcoming events tracked.